English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

BACKGROUND The protein Galectin-1 (gal-1) is known to be involved in proliferation and progression of several malignancies. The allosteric gal-1 inhibitor OTX-008 has an antiproliferative effect on various tumors in vitro and in vivo. However, the effect of OTX-008 on patient derived GBM cultures is unknown. The aim of our study was to investigate the antiproliferative effects of OTX-008 on U87-MG and A172 cells, patient derived GBM cultures, and cultured human astrocytes (HCA). MATERIAL AND METHODS GBM specimens from 10 patients were intraoperatively retrieved out of the 5-ALA-positive areas and were cultured in DMEM. In these cell cultures, U87-MG and A172 cell lines, and in HCA the gal-1 expression was determined by quantitative RT-PCR. Gal-1 expression below the median was defined as low-gal-1 expression (LGE), above as high-gal-1 expression (HGE). OTX-008 was administered and cell viability was assessed after 72h with MTT assay. Dose-response curves and influence of gal-1 expression were calculated by probit analysis in a logit model with logarithmic transformation of x-axis. Comparison between MGMT promotor methylated and unmethylated cells was performed using the Mann-Whitney U test. RESULTS OTX-008 inhibited cell proliferation of all 10 patient derived GBM cell cultures with a mean ED50 of 34.28 (95% CI: 20.29- 61.57) μM and a mean ED95 of 100.90 (59.30- 199.33) μM. Antiproliferative effects of OTX-008 for U87-MG and A172 cells were found with an ED50 of 17.44 (95% CI: 13.24- 22.52) μM and 33.36 (95% CI: 24.30- 45.86) μM. In 5 cell cultures of the patient derived cells LGE and in the other 5 HGE was determined. Probit analysis showed an ED50 of 20.43 (95% CI: 16.03- 24.89) μM for the LGE group and an ED50 of 33.98 (95% CI: 28.15- 40.89) μM for the HGE-group. Between MGMT-promotor methylated and unmethylated cells no statistically significant difference for the ED50 was observed (38.36 vs. 31.56; P=0.454). Probit analysis of OTX-008 administration in HCA showed no dose-response-relation. CONCLUSION OTX-008 has antiproliferative effects on human glioblastoma cells independent of MGMT-promotor methylation status. The sensitivity of GBM cells to OTX-008 depends on the gal-1 expression level. In HCA no effect on cell viability was observed. OTX-008 seems a promising novel substance in glioblastoma therapy.

P11.38 The Galectin-1 inhibitor OTX-008 has antiproliferative effects on human glioblastoma cells independent of MGMT-promotor status